Institut National De La Sante Et De La Recherche Medicale

Universite Dé Lorraine

Assistance Publique - Hopitaux De Paris (aphp)

Duke University

UniversitÉ Paris Descartes

Aphp (Assistance Publique-Hôpitaux De Paris)

Inotrem

Assistance Publique-hopitaux De Paris

Sorbonne Université

Universite Paris Cité

Aphp

Inserm

Hafid Ait-Oufella

Alain Tedgui

Sebastien Gibot

Marc Derive

Amir Boufenzer

Thomas F Tedder

Ziad Mallat

Nicolas Danchin

Pierre Louis Tharaux

Tabasomme Simon

Sébastien Gibot

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

B cell depleting agent for the treatment of atherosclerosis

A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

Methods and kits for predicting the risk of having a cardiovascular disease or event

The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.

Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction

The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Methods for producing a non human model for aortic aneurysm

Growing community of inventors

Charenton-le-Pont, France

Hafid Ait-Oufella